MX2020009950A - Moduladores de receptores acoplados a proteina g. - Google Patents

Moduladores de receptores acoplados a proteina g.

Info

Publication number
MX2020009950A
MX2020009950A MX2020009950A MX2020009950A MX2020009950A MX 2020009950 A MX2020009950 A MX 2020009950A MX 2020009950 A MX2020009950 A MX 2020009950A MX 2020009950 A MX2020009950 A MX 2020009950A MX 2020009950 A MX2020009950 A MX 2020009950A
Authority
MX
Mexico
Prior art keywords
chemical entities
glp
gipr
disorder
disease
Prior art date
Application number
MX2020009950A
Other languages
English (en)
Inventor
Daniel Erlanson
Johan Enquist
Shyam Krishnan
Suman Atwal
Raymond V Fucini
Stig Hansen
Andrew Sawayama
Steven Sethofer
Original Assignee
Carmot Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carmot Therapeutics Inc filed Critical Carmot Therapeutics Inc
Publication of MX2020009950A publication Critical patent/MX2020009950A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a entidades químicas (por ejemplo, un compuesto o una sal y/o hidrato y/o profármaco del compuesto farmacéuticamente aceptable) que modulan (por ejemplo, agonizan o agonizan parcialmente o antagonizan a) el receptor del péptido-1 similar al glucagón ("GLP-1R") y/o el receptor del polipéptido inhibidor gástrico ("GIPR"). Las entidades químicas son útiles, por ejemplo, para tratar un sujeto (por ejemplo, un humano) que tiene una enfermedad, trastorno, o condición en el cual la modulación (por ejemplo, agonismo, agonismo parcial o antagonismo) de las actividades del GLP-1R y/o GIPR es benéfica para el tratamiento o prevención de la patología subyacente y/o síntomas y/o progreso de la enfermedad, trastorno, o condición. En algunas modalidades, la modulación resulta en un mejoramiento de (por ejemplo, un incremento en) niveles existentes (por ejemplo, niveles normales o por debajo de los normales) de la actividad de GLP-1R y/o GIPR (por ejemplo, señalización). En algunas modalidades, las entidades químicas descritas en la presente modulan además (por ejemplo, atenúan, desacoplan) la señalización de ß-arrestina con relación a aquella que se observa con el ligando nativo. Esta descripción también caracteriza composiciones así como también otros métodos para usar y elaborar tales entidades químicas.
MX2020009950A 2018-03-23 2019-03-22 Moduladores de receptores acoplados a proteina g. MX2020009950A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647604P 2018-03-23 2018-03-23
PCT/US2019/023726 WO2019183577A1 (en) 2018-03-23 2019-03-22 Modulators of g-protein coupled receptors

Publications (1)

Publication Number Publication Date
MX2020009950A true MX2020009950A (es) 2021-04-28

Family

ID=67986596

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020009950A MX2020009950A (es) 2018-03-23 2019-03-22 Moduladores de receptores acoplados a proteina g.
MX2025006799A MX2025006799A (es) 2018-03-23 2020-09-23 Moduladores de receptores acoplados a la proteina-g

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025006799A MX2025006799A (es) 2018-03-23 2020-09-23 Moduladores de receptores acoplados a la proteina-g

Country Status (17)

Country Link
US (2) US11535660B1 (es)
EP (1) EP3768294A4 (es)
JP (2) JP7526716B2 (es)
CN (1) CN112236161A (es)
AR (1) AR115016A1 (es)
AU (2) AU2019237507B2 (es)
BR (1) BR112020019148A2 (es)
CA (1) CA3094820A1 (es)
EA (1) EA202092269A1 (es)
IL (3) IL277495B2 (es)
MX (2) MX2020009950A (es)
MY (1) MY205468A (es)
PH (1) PH12020551539A1 (es)
SG (1) SG11202009338SA (es)
TW (2) TWI840348B (es)
UA (1) UA129084C2 (es)
WO (1) WO2019183577A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019237507B2 (en) * 2018-03-23 2025-04-03 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
JP7688891B2 (ja) * 2021-01-18 2025-06-05 国立大学法人東海国立大学機構 ペプチド
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
IL308392A (en) 2021-05-13 2024-01-01 Carmot Therapeutics Inc G protein-coupled receptor modulators
IL311411A (en) 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
KR20240064272A (ko) * 2022-11-04 2024-05-13 주식회사 엘지화학 불소계 화합물, 광중합성 조성물, 홀로그램 기록 매체, 이의 제조 방법 및 이를 포함하는 광학 소자
CN119095890A (zh) 2022-11-04 2024-12-06 株式会社Lg化学 全息图记录介质和包括其的光学元件
EP4634152A1 (en) 2022-12-15 2025-10-22 Syngenta Crop Protection AG Novel bicyclic-carboxamide compounds useful as pesticides
WO2024217497A1 (en) * 2023-04-21 2024-10-24 The University Of Hong Kong Novel small molecule agonists of insulin receptor (insr) as anti-diabetes drugs
CN121358759A (zh) * 2023-06-22 2026-01-16 卡莫特治疗学股份有限公司 Glp-1r/gipr激动剂及其前体的合成
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
US20260035406A1 (en) * 2024-07-31 2026-02-05 Carmot Therapeutics Inc. Synthesis of glp-1r/gipr agonists
WO2026073030A1 (en) 2024-09-27 2026-04-02 Carmot Therapeutics Inc. Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
AU2610899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO2000034331A2 (en) * 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
CN1364167A (zh) 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
CA2383794A1 (en) 1999-09-07 2001-03-15 Conjuchem Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
EP1556032A1 (en) 2002-11-01 2005-07-27 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
US20050059605A1 (en) * 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
KR101241862B1 (ko) * 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
CA2551610A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
JP2008539735A (ja) * 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical COMPOUND OF PHENOXYALKANOIC ACID
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CN101420941A (zh) * 2006-04-11 2009-04-29 艾尼纳制药公司 Gpr119受体激动剂用于增加骨质量和用于治疗骨质疏松症的用途,和其相关组合疗法
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
WO2008021560A2 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
UA97257C2 (en) 2006-10-19 2012-01-25 Такеда Фармасьютикал Компани Лимитед Indole derivatives
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
MX2009008103A (es) 2007-02-09 2009-08-18 Takeda Pharmaceutical Compuestos anulares fusionados como agonistas parciales de prar-gamma.
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
TWI474835B (zh) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
US20120021979A1 (en) 2010-06-24 2012-01-26 Vanderbilt University GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
WO2013148579A1 (en) 2012-03-29 2013-10-03 Cebix Inc. Pegylated c-peptide
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
JP6548579B2 (ja) * 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
US9766239B2 (en) 2013-03-13 2017-09-19 Arizona Board Of Regents On Behalf Of Arizona State University Synbodies for detection of human norovirus
CN105555756B (zh) * 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
WO2015031268A1 (en) 2013-08-26 2015-03-05 Arizona Board Of Regents On Behalf Of Arizona State University High affinity synbodies for influenza
EP3218414A1 (en) * 2014-11-14 2017-09-20 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
CN105219802A (zh) * 2015-10-10 2016-01-06 广西大学 胰岛组织特异性表达GIPRdn慢病毒载体及其应用
GB2551945B (en) * 2015-12-18 2021-09-08 Heptares Therapeutics Ltd Novel GLP-1 receptor agonist peptides
AU2019237507B2 (en) * 2018-03-23 2025-04-03 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors

Also Published As

Publication number Publication date
BR112020019148A2 (pt) 2021-01-26
JP2021531259A (ja) 2021-11-18
AU2019237507A1 (en) 2020-10-08
IL277495B2 (en) 2024-08-01
JP7526716B2 (ja) 2024-08-01
IL323264A (en) 2025-11-01
IL277495A (en) 2020-11-30
WO2019183577A1 (en) 2019-09-26
SG11202009338SA (en) 2020-10-29
IL311177A (en) 2024-04-01
US11535660B1 (en) 2022-12-27
IL277495B1 (en) 2024-04-01
IL311177B2 (en) 2026-02-01
AU2025202679A1 (en) 2025-05-22
MX2025006799A (es) 2025-07-01
UA129084C2 (uk) 2025-01-08
TW202012432A (zh) 2020-04-01
AR115016A1 (es) 2020-11-18
AU2019237507B2 (en) 2025-04-03
TWI840348B (zh) 2024-05-01
US20230357347A1 (en) 2023-11-09
PH12020551539A1 (en) 2021-06-07
KR20210008834A (ko) 2021-01-25
EA202092269A1 (ru) 2020-12-14
MY205468A (en) 2024-10-22
CN112236161A (zh) 2021-01-15
CA3094820A1 (en) 2019-09-26
JP2024156720A (ja) 2024-11-06
EP3768294A4 (en) 2022-05-04
EP3768294A1 (en) 2021-01-27
TW202444405A (zh) 2024-11-16
IL311177B1 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
AR115016A1 (es) Moduladores de receptores acoplados a la proteína g
ECSP23093673A (es) Moduladores de los receptores acoplados a proteínas g
CL2017001760A1 (es) Compuestos co-agonistas de gip y glp-1
PE20212198A1 (es) Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
CL2021003419A1 (es) Agonistas del receptor del péptido-1 similar al glucagón
CR20210040A (es) Compuestos coagonistas de gip/glp1
CO2021010075A2 (es) Receptores de antígenos quiméricos de gprc5d y células que los expresan
PE20212077A1 (es) Nuevos compuestos sulfonamida de carboxamida
MX2021011278A (es) Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un farmaco.
MX2020002977A (es) Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
MX382502B (es) Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).
EA201891620A1 (ru) Ингибиторы взаимодействующей с рецептором протеинкиназы 1
BR112014016643A2 (pt) estruturas fibrosas contendo ativo com múltiplas regiões tendo densidades diferentes
CL2017002911A1 (es) Tratamiento de la hipoglucemia posbariátrica con antagonistas de glp-1.
MX2019002437A (es) Metodos para tratar la resistencia severa a la insulina interfiriendo con la señalizacion del receptor de glucagon.
PE20091326A1 (es) Anticuerpos anti-trkb mejorados
MX2025015078A (es) Formulaciones de analogos peptidicos de oxintomodulina
EA202090928A1 (ru) Имипридоны для глиом
BR112023025340A2 (pt) Compostos de triptamina fluorada, análogos dos mesmos e métodos usando os mesmos
BR112022001255A2 (pt) Métodos de tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn
On et al. Evolution of parathyroid hormone receptor family and their ligands in vertebrate
MX381977B (es) Moduladores del receptor de péptido 1 tipo glucagón.
BR112022009152A2 (pt) Processo de fabricação para preparar células t expressando receptores de antígenos quiméricos
BR112015017909A2 (pt) redução do risco de doença autoimune
BR112015015933A2 (pt) colocação em cache com zero cópia